FDA Approves GSK’s HIBSAGO; Phase 3 Data Show 19% Functional Cure Rate
Ionis Pharmaceuticals said its partner GSK received U.S. FDA approval for HIBSAGO (bepirovirsen). The Phase 3 B-Well trials showed a 19% functional cure rate.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.